RECRUITING Phase 2 ClinicalTrials.gov

Comparing Moderately and Ultra Hypofractionated Radiation Treatments for Post-operative Prostate Cancer

Sponsor: University Health Network, Toronto • ClinicalTrials.gov ID: NCT06409910

Registry updated: 2026-10-08

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.

Interventions

Radiotherapy (Radiation)
Non-institutional-standard radiotherapy

Eligibility criteria

Inclusion Criteria: 1. Age \>/= 18 years 2. Able to provide informed consent 3. Histologic diagnosis of prostate adenocarcinoma 4. ECOG performance status 0-1 5. Previous radical prostatectomy \> 6 months prior to radiotherapy start date 6. Planned to receive post-operative radiation Exclusion Criteria: 1. Prior pelvic radiotherapy 2. Contraindications to radiotherapy 3. Confirmed metastases (if scan has been done for clinical care) 4. Participants with visible disease in the prostate bed or pelvic lymph nodes on imaging are not eligible for treatment on study.

Conditions

Post-Operative Prostate Cancer

Locations

London Health Sciences Centre — London, Ontario, Canada
Sunnybrook Health Sciences Centre - Sunnybrook Research Institute — Toronto, Ontario, Canada
University Health Network - Princess Margaret Cancer Centre — Toronto, Ontario, Canada

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment